Compassionate Use of Omegaven in Preterm Neonates with Parenteral Nutrition Associated Direct Hyperbilirubinemia
Journal of Pediatrics & Neonatal Care · 2014
DOI: 10.15406/jpnc.2014.01.00004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatrics & Neonatal Care, 2014. Verfasst von Thomas Havranek. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Intravenous fish-oil-based fat emulsions enriched with omega 3 fatty acids, such as Omegaven, are available through investigational new drug (IND) and emergency IND (eIND) applications to ameliorate parenteral nutrition associated liver disease (PNALD).
Objective
To describe changes in conjugated, direct bilirubin in the cohort of preterm neonates before and after continuous Omegaven administration.Design/Methods: Between April 2009 and July 2011, under compassionate use protocols at St Louis University/Cardinal Glennon Children's Medical Center and George Washington University/Children's National Medical Center, preterm neonates receiving parenteral nutrition (PN) with soybean emulsions were treated with Omegaven and prospectively followed.Eligibility requirements included serum direct bilirubin levels ≥ 3 mg/dL and predicted PN duration of > 21 days.Omegaven stopping criteria were either the serum direct bilirubin level < 1 mg/dL or sufficient tolerance of enteral nutrition, prompting PN discontinuation.To assure sufficient Omegaven therapeutic exposure, only neonates receiving Omegaven for ≥ 30 days were included in the data analysis.Wilcoxon signedrank test was used to assess serum direct bilirubin change.
Results
Data of 17 very low birth weight preterm neonates were analysed: over a median of 64 days of Omegaven therapy, serum direct bilirubin level decreased significantly (6.16 mg/dl vs 4.82 mg/dl, p=0.035).Importantly, followed safety markers were unchanged during therapy. Conclusions:Modest, yet statistically significant decrease in serum direct bilirubin levels was associated with fish-oil based lipid emulsions use in our cohort of cholestatic preterm neonates.
Zitieren
APA
Havranek, T. (2014). Compassionate Use of Omegaven in Preterm Neonates with Parenteral Nutrition Associated Direct Hyperbilirubinemia. Journal of Pediatrics & Neonatal Care. https://doi.org/10.15406/jpnc.2014.01.00004
Vancouver
Havranek T. Compassionate Use of Omegaven in Preterm Neonates with Parenteral Nutrition Associated Direct Hyperbilirubinemia. Journal of Pediatrics & Neonatal Care. 2014. doi:10.15406/jpnc.2014.01.00004
BibTeX
@article{Havranek2014,
author = {Havranek, Thomas},
title = {Compassionate Use of Omegaven in Preterm Neonates with Parenteral Nutrition Associated Direct Hyperbilirubinemia},
journal = {Journal of Pediatrics & Neonatal Care},
year = {2014},
doi = {10.15406/jpnc.2014.01.00004}
}
EUVIMED